<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277158</url>
  </required_header>
  <id_info>
    <org_study_id>DP03182014</org_study_id>
    <nct_id>NCT02277158</nct_id>
  </id_info>
  <brief_title>Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.</brief_title>
  <official_title>A Phase I Study of Concurrent Radiotherapy and Tegafur, Gimeracil and Oteracil Potassium Capsule(S-1) as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose and safety of S-1 plus
      radiotherapy for patients with rectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This stage I study is designed to evaluate the appropriate dose of S-1 plus radiotherapy for
      patients with R0 resection of rectal cancer for stage II-III patients(AJCC 7th). To evaluate
      safety, data on adverse events will be collected from the time of enrollment until withdrawn
      of complete whole study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>6weeks (42 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>6weeks (42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6weeks (42 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>S-1 CCRT</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  R0 resection of histologically proved stage II/III rectal cancer;

          -  18-75 years old;

          -  No previous radiotherapy or chemotherapy for rectal cancer;

          -  Performance status of ECOG 0,1;

          -  Adequate organ function defined as below:

             i. WBC ≥ 4,000/mm^3 ii. ANC ≥ 1,500/mm^3 iii. Hemoglobin ≥ 10g/dL iv. Platelet ≥
             100,000/m^3 v. Total bilirubin ≤ 1.5ULN vi. AST/ALT ≤ 1.5ULN vii. Serum creatinine ≤
             1.5ULN or creatinine clearance rate ≥ 60ml/min、Urea nitrogen ≤ 1.5ULN viii. Protein in
             urine dipstick test＜1+; if the test result ＞1+ ,total protein in urea must ＜500mg
             within 24 hours

          -  Able to receive oral administration

          -  Informed consent

        Exclusion Criteria:

          -  Hypersensitive to S-1 or its excipients

          -  Pulmonary fibrosis or interstitial pneumonitis found within 28 days prior to
             registration

          -  Significant co-morbid medical conditions, including, but not limited to, heart
             failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or
             paralytic ileus, or poorly controlled diabetes

          -  Received any investigational drug or anti-cancer agent

          -  Pregnant or lactating female or pregnancy test positive

          -  Severe mental disorder

          -  Judged ineligible by physicians for participation in the study due to safety concern.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenzhou Yang, MD, PhD</last_name>
    <phone>＋86-02368811229</phone>
    <email>yangzz1970@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhenzhou-Yang</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenzhou Yang, PHD</last_name>
      <email>yangzz1970@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>November 30, 2014</last_update_submitted>
  <last_update_submitted_qc>November 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhen-zhou Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>S-1</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

